

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

NCT07104721

Status	RECRUITING
Phase	Phase 1
Sponsor	China Immunotech (Beijing) Biotechnology Co., Ltd.
Enrollment	18 participants

Key Eligibility Criteria

Inclusion (40)

- \. Age ranges from 18 to 65 years old (including threshold), regardless of gender.
 - \. Essential Organ Function Criteria:
 - Bone marrow: Neutrophils $\geq 1 \times 10^9/L$ (within 2 weeks, excluding granulocyte colony-stimulating factor use); Hemoglobin ≥ 60 g/L.
 - Liver: ALT/AST $\leq 3 \times ULN$ (disease-related elevations permitted). TBIL $\leq 1.5 \times ULN$ (disease-related elevations permitted).
 - Renal: CrCl ≥ 30 mL/min (Cockcroft-Gault formula, excluding acute declines).
- ... and 35 more (see full listing online)

Exclusion (14)

- Individuals with a severe history of drug allergies or those with an allergic constitution;
 - Individuals with existing or suspected uncontrolled or treatable fungal, bacterial, viral, or other infections;
 - Subjects with central nervous system diseases (excluding those with a history of epilepsy, psychiatric disorders, organic brain disease syndromes, cerebrovascular accidents, encephalitis, or central nervous system vasculitis resulting from the underlying disease);
 - Subjects whose cardiac function cannot tolerate the study interventions;
 - Subjects with congenital immunoglobulin deficiencies;
- ... and 9 more (see full listing online)

Locations (1 total)

The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China